Question: What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Description: The Chemical can be represented with the SMILES C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.
Answer: Phase 3 Clinical Trials
{#Question|Q!}: {quest#}
{#Constraint:|Description:|!} The {#Molecule|Compound|Chemical!} {#has the|can be represented with the!} {SMILES__description} {SMILES#}.
{#Answer|Result|Answer!}: {answ#}
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonicacid
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.